Notwithstanding numerous setbacks, many MDM2 inhibitors have now progressed into late-phase medical progress. New approaches have also been made to enhance the efficacy of MDM2 inhibitors and to mitigate their on-concentrate on toxicity. In this particular critique, we summarize the progress and pro